This information is intended for US healthcare professionals.

Brought to you by Gilead Oncology logo in white text.

Actor portrayal.

HOW DOES HR-MDS USE
CD47 OVEREXPRESSION
TO HIDE FROM THE
IMMUNE SYSTEM?1

New targets continue to emerge that have
the potential to advance the investigation
into higher-risk MDS.

Investigate Further

Actor portrayal.

Watch NEW developments in the ONGOING case against higher-risk MDS

TV screen showing MDS video.
Cover
Cover

STAY UP TO DATE
AS
THE CASE EVOLVES

Register for Updates

Investigate clues about
macrophages and CD47

Explore CD47 and the Immune System

Could research into a new class of immunotherapy advance our understanding of HR-MDS?

Explore Research Into Higher-Risk MDS

HR-MDS, higher-risk myelodysplastic syndrome; MDS, myelodysplastic syndrome.

Reference: 1. Chao MP, Takimoto CH, Feng DD, et al. Front Oncol. 2020;9:1380. doi:10.3389/fonc.2019.01380

GILEAD and the GILEAD Logo are trademarks of Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404 © 2022 Gilead Sciences, Inc. All rights reserved. US-UNBP-1291 11/22